13th Scientific MeetingFebruary 16th-19th, 2017Florence (Italy)

AOPT Association for OcularPharmacology and Therapeutics

www.aopt.org

OCULAR THERAPEUTICS: VISION OF HOPE IN A CHANGING WORLD

Organizing Secreteriat www.medeacom.org

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICSIs the only multidisciplinary, peer-reviewed journal providing basic and clinical research about biopharmaceuticals that have the po-tential to prevent, treat, and/or diagnose ocu-lar diseases and disorders. The journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of biopharmaceuti-cals for the treatment of ophthalmic disorders.

WHO WE AREThe Association for Ocular Pharmacology and Therapeutics in is a global not-for-profit organization for scientists and individuals from all disciplines related to ocular pharmacology and its therapeutic ap-plications. AOPT has a diverse, multinational membership compo-sed of preclinical and clinical scientists, students and healthcare pro-fessionals. Members are from academic institutions, pharma and biotech industries, device companies, clinics and private practice.

ATTENDEEThe AOPT Scientific Meeting is an international conference focused on bringing together clinicians and other eye care professionals, academic and industry scientists from around the globe to share their exciting new discoveries related to the treatment of ocular diseases. We anticipate ha-ving attendees coming from more than 15 different countries, including physicians, researchers, professors, ophthalmologists, and optometrists.

OUR JOURNAL

facebook.com / aopt - meeting

www.linkedin.com/company/aopt-meetings

SeSSion i (ThurSday, February 16, 17:30)TRANSLATIONAL OPHTHALMOLOGY AND BIOMARKER RESEARCH IN EYE DISEASE: IS IT TIME FOR A TARGET THERAPY IN OPHTHALMOLOGY? oliver ZeiTZ, dan STamer SeSSion ii (Friday, February 17, 09:00)NEW INSIGHTS IN THE THERAPEUTIC APPROACHES TO AMD: IS THERE A HOPE FOR AN AFFORDABLE TREATMENT?CaThy boweS riCkman, Chiara eandi

SeSSion iii (Friday, February 17, 10:45)DIABETIC RETINOPATHY, A DISEASE OF INCREASING CONCERN marina ZiChe, aSh Jayagopal SeSSion iv (Friday, February 17, 13:15)REGULATORY ISSUES GOVERNING OPHTHALMIC DRUGS: PHARMACOECONOMICS AND DRUG DEVELOPMENT IN A CHANGING WORLD Filippo drago, peTer kador SeSSion v (Friday, February 17, 15:00) YOUNG INVESTIGATOR SESSION malinda FiTZgerald, aleSSia paSCale SeSSion vi (SaTurday, February 18, 09:00)ADVANCES IN OCULAR DRUG DELIVERY AND ITS ROLE IN PATIENT’S COMPLIANCE uday kompella, Claudio buColo SeSSion vii (SaTurday, February 18, 10:45)GLAUCOMA: RESEARCH AND DRUG DISCOVERY IN THE XXI CENTURY Carol ToriS, STeFano gandolFi SeSSion viii (SaTurday, February 18, 13:15)NEUROPROTECTION IN OPHTHALMOLOGY: DO WE STILL NEED IT? neville oSborne, iok-hou pang SeSSion iX (SaTurday, February 18, 15:00)EYE IMMUNE DISORDERS IN THE TIME OF GLOBALIZED MEDICINE pedram hamrah, Juana gallar

SeSSion X (Sunday, February 19, 09:00)GENETIC AND RARE EYE DISEASES: A CLOSE GLANCE TO ORPHAN DRUGS Cheryl rowe-rendlemand, enriCa STreTToi

SeSSion Xi (Sunday, February 19, 10:45)OCULAR BLOOD FLOW: AN ISSUE FOR DIAGNOSIS AND THERAPY JeFF kiel, leopold SChmeTTerer SeSSion Xii (Sunday, February 19, 13:15)TREATMENT OF REFRACTIVE ERROR DEFECTS: WHAT IS THE ROLE OF OCULAR PHARMACOLOGY? ChriSTine F. wildSoeT, CaTerina gagliano SeSSion Xiii (Sunday, February 19, 15:00)OCULAR SURFACE DISEASES: AN EMERGING CONCERN IN OPHTHALMOLOGY david goldblum, ChriSTophe baudouin poSTer SeSSion (Friday, February 17, 17:00) ShuSheng wang, Julie Crider panel diSCuSSion: bridging induSTry, aCademia and CliniCianS For The beneFiT oF The global mediCine (SaTurday, February 18, 16:45)aChim krauSS, TereSio aviTabile

SESSIONS & TOPICS | Moderators

KEYNOTE SPEAKER ERIC PEARLMAN PhD.DIRECTOR of INSTITUTE FOR IMMUNOLOGYUniversity of California, Irvine

FUNGAL KERATITIS, A MAJOR CAUSE OF BLINDNESS AND VISUAL IMPAIRMENT WORLDWIDEProf. Pearlman started his studies at University of Glasgow, he earned his PhD in Microbiology at University of Texas (Health Sciences Center – San Antonio). He started its academic research studying “river blindness” – onchocerciasis. Eric Pearlman was part of the research group that found out that a bacterium, living inside the worm Onchocerca volvulus, was the real cause of inflammation and blindness, rather than the worm itself. These results have been published on Science in 2002. In 2005-2006, there was an outbreak of fungal keratitis in USA, northern Europe and UK; those corneal infections were difficult to treat and were related to contamination by Fusarium solani of a lens care product. Furthermore, this fungal keratitis is a major cause of blindness in developing world, because spores (conidia) are common in the soil and in the air of rural areas. Currently, Pearlman’s research is focused on Fusarium keratitis and his research group developed an animal model of this disease, in order to identify the biochemical mechanism of this infection and best pharmacological targets, to further develop new therapies.

REGISTRATION FEES EARLY Regular members € 375 Non-members € 475 Students, Post-docs € 200

Registration fee includes: Welcome reception, gala dinner, 3 lunches, coffee breaks

ABSTRACT SUBMISSION (www.aopt.org)

Opens August 29, 2016 Regular attendee Deadline: November 30, 2016 Travel award applicant* Deadline: October 21, 2016*Only graduate students, medical students, other health professional students, post-doctoral fellows, residents, and faculty below the rank of associate professor